NCCN Oncology Research Program (ORP)


NCCN ORP Mission Statement
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer.

Guiding Principles

  1. Study both FDA-approved and investigational agents/devices, to seek novel enhanced, effective, and efficient cancer therapy.
  2. Develop new insights into cancer care delivery outcomes and quality, as well as identify solutions to barriers affecting optimal cancer management.
  3. Increase opportunities for NCCN Member Institution faculty to participate in oncologic investigation and support those who are, or will become, leaders in cancer research.
  4. Demonstrate that constructive, appropriate, and transparent collaboration between academia and industry results in valuable knowledge and improved cancer management.
  5. Ensure the dissemination of knowledge gained through the program to the medical community at large through presentations at meetings and/or publication in peer-reviewed journals.

Current Opportunities

NCCN Taiho Futibatinib Research Grant Opportunity: Submit by April 29, 2020
The NCCN Oncology Research Program (ORP) is organized to obtain funding to support scientifically meritorious research studies (clinical trials) at NCCN Member Institutions. Policies and standards for the program are set by the NCCN Investigator Steering Committee, comprised of senior research physicians appointed by each NCCN Member Institution. The NCCN ORP has received millions of dollars in research grants from major pharmaceutical companies to support investigator-initiated trials, which explore new venues of clinical investigation that answer important research questions. Studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents, drug resistance, or are directed toward exploring extended uses for specific agents.
Leading clinicians and investigators from NCCN Member Institutions evaluate promising new chemical entities or biological agents.